EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry

Abstract

With nearly all cancer deaths a result of metastasis, elucidating novel pro-metastatic cellular adaptations could provide new therapeutic targets. Here, we show that overexpression of the EPS15-Homology Domain-containing 2 (EHD2) protein in a large subset of breast cancers (BCs), especially the triple-negative (TNBC) and HER2+ subtypes, correlates with shorter patient survival. The mRNAs for EHD2 and Caveolin-1/2, structural components of caveolae, show co-overexpression across breast tumors, predicting shorter survival in basal-like BC. EHD2 shRNA knockdown and CRISPR-Cas9 knockout with mouse Ehd2 rescue, in TNBC cell line models demonstrate a major positive role of EHD2 in promoting tumorigenesis and metastasis. Mechanistically, we link these roles of EHD2 to store-operated calcium entry (SOCE), with EHD2-dependent stabilization of plasma membrane caveolae ensuring high cell surface expression of the SOCE-linked calcium channel Orai1. The novel EHD2-SOCE oncogenic axis represents a potential therapeutic target in EHD2 and CAV1/2-overexpressing BC.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting file.

Article and author information

Author details

  1. Haitao Luan

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  2. Timothy A Bielecki

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  3. Bhopal C Mohapatra

    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  4. Namista Islam

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  5. Insha Mushtaq

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  6. Aaqib M Bhat

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  7. Sameer Mirza

    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  8. Sukanya Chakraborty

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  9. Mohsin Raza

    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  10. Matthew D Storck

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  11. Michael S Toss

    Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
    Competing interests
    No competing interests declared.
  12. Jane L Meza

    Departments of Biostatistics, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  13. Wallace B Thoreson

    Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7104-042X
  14. Donald W Coulter

    Department of Pediatrics, University of Nebraska Medical Center, Omaha, United States
    Competing interests
    No competing interests declared.
  15. Emad A Rakha

    Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
    Competing interests
    No competing interests declared.
  16. Vimla Band

    Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, United States
    For correspondence
    vband@unmc.edu
    Competing interests
    Vimla Band, received funding from Nimbus Therapeutics for an unrelated project..
  17. Hamid Band

    Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, United States
    For correspondence
    hband@unmc.edu
    Competing interests
    Hamid Band, received funding from Nimbus Therapeutics for an unrelated project..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4996-9002

Funding

Department of Defence (W81XWH-17-1-0616 and W81XWH-20-1-0058)

  • Hamid Band

Department of Defence (W81XWH-20-1-0546)

  • Vimla Band

National Institutes of Health (R21CA241055 and R03CA253193)

  • Vimla Band

Fred and Pamela Buffett Cancer Center (Pilot grant)

  • Vimla Band

Fred and Pamela Buffett Cancer Center (Pilot grant)

  • Hamid Band

University of Nebraska Medical Center (Graduate Student Fellowships)

  • Timothy A Bielecki

University of Nebraska Medical Center (Graduate Student Fellowships)

  • Aaqib M Bhat

University of Nebraska Medical Center (Graduate Student Fellowships)

  • Sukanya Chakraborty

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All mouse xenograft and treatment studies were pre-approved by the UNMC Institutional Animal Care and Use Committee (IACUC) under the IACUC protocol number 19-115-10-FC and conducted strictly according to the pre-approved procedures, in compliance with Federal and State guidelines.

Human subjects: Human tissues were collected and processed at the Nottingham University Hospital, United Kingdom. This study was approved by the Yorkshire & The Humber-Leeds East Research Ethics Committee (REC reference: 19/YH/0293) under the IRAS Project ID: 266925. Informed consent was obtained from all individuals prior to surgery for the use of their tissue materials in research. All samples were properly coded and anonymized in accordance with the approved protocols.

Copyright

© 2023, Luan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,438
    views
  • 230
    downloads
  • 8
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Haitao Luan
  2. Timothy A Bielecki
  3. Bhopal C Mohapatra
  4. Namista Islam
  5. Insha Mushtaq
  6. Aaqib M Bhat
  7. Sameer Mirza
  8. Sukanya Chakraborty
  9. Mohsin Raza
  10. Matthew D Storck
  11. Michael S Toss
  12. Jane L Meza
  13. Wallace B Thoreson
  14. Donald W Coulter
  15. Emad A Rakha
  16. Vimla Band
  17. Hamid Band
(2023)
EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry
eLife 12:e81288.
https://doi.org/10.7554/eLife.81288

Share this article

https://doi.org/10.7554/eLife.81288

Further reading

    1. Cancer Biology
    2. Cell Biology
    Maojin Tian, Le Yang ... Peiqing Zhao
    Research Article

    TIPE (TNFAIP8) has been identified as an oncogene and participates in tumor biology. However, how its role in the metabolism of tumor cells during melanoma development remains unclear. Here, we demonstrated that TIPE promoted glycolysis by interacting with pyruvate kinase M2 (PKM2) in melanoma. We found that TIPE-induced PKM2 dimerization, thereby facilitating its translocation from the cytoplasm to the nucleus. TIPE-mediated PKM2 dimerization consequently promoted HIF-1α activation and glycolysis, which contributed to melanoma progression and increased its stemness features. Notably, TIPE specifically phosphorylated PKM2 at Ser 37 in an extracellular signal-regulated kinase (ERK)-dependent manner. Consistently, the expression of TIPE was positively correlated with the levels of PKM2 Ser37 phosphorylation and cancer stem cell (CSC) markers in melanoma tissues from clinical samples and tumor bearing mice. In summary, our findings indicate that the TIPE/PKM2/HIF-1α signaling pathway plays a pivotal role in promoting CSC properties by facilitating the glycolysis, which would provide a promising therapeutic target for melanoma intervention.

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Ananda Kishore Mukherjee, Subhajit Dutta ... Shantanu Chowdhury
    Research Article

    Telomeres are crucial for cancer progression. Immune signalling in the tumour microenvironment has been shown to be very important in cancer prognosis. However, the mechanisms by which telomeres might affect tumour immune response remain poorly understood. Here, we observed that interleukin-1 signalling is telomere-length dependent in cancer cells. Mechanistically, non-telomeric TRF2 (telomeric repeat binding factor 2) binding at the IL-1-receptor type-1 (IL1R1) promoter was found to be affected by telomere length. Enhanced TRF2 binding at the IL1R1 promoter in cells with short telomeres directly recruited the histone-acetyl-transferase (HAT) p300, and consequent H3K27 acetylation activated IL1R1. This altered NF-kappa B signalling and affected downstream cytokines like IL6, IL8, and TNF. Further, IL1R1 expression was telomere-sensitive in triple-negative breast cancer (TNBC) clinical samples. Infiltration of tumour-associated macrophages (TAM) was also sensitive to the length of tumour cell telomeres and highly correlated with IL1R1 expression. The use of both IL1 Receptor antagonist (IL1RA) and IL1R1 targeting ligands could abrogate M2 macrophage infiltration in TNBC tumour organoids. In summary, using TNBC cancer tissue (>90 patients), tumour-derived organoids, cancer cells, and xenograft tumours with either long or short telomeres, we uncovered a heretofore undeciphered function of telomeres in modulating IL1 signalling and tumour immunity.